Table 1 Demographics.
HC (n = 24) | PD (n = 27) | p value | |
|---|---|---|---|
Age at enrollment (years) | 66.5 ± 8.1 | 69.3 ± 8.4 | 0.228 |
Gender (female/male) | 16/8 | 8/19 | 0.008 |
Right-handed | 100% | 81% | 0.085 |
OFF UPDRS Part III (motor) Score | 4.1 ± 3.4 | 24.4 ± 11.2 | < 0.001 |
OFF Total UPDRS Score | 6.7 ± 4.5 | 40.1 ± 18.5 | < 0.001 |
ON UPDRS Part III (motor) Score | 16.6 ± 10.3 (n = 22) | ||
ON Total UPDRS Score | 28.1 ± 17.4 (n = 22) | ||
Motor UPDRS (OFF–ON) | 7.8 ± 6.9 (n = 22) | ||
MOCA score | 28.0 ± 1.7 | 26.1 ± 3.4 | 0.013 |
HAM-D | 2.9 ± 3.2 | 6.3 ± 4.7 | 0.004 |
HAM-A | 2.7 ± 3.0 | 4.7 ± 3.6 | 0.018 |
Right side more disease affected (MA) | – | 56% | |
PIGD phenotype at visit | – | 41% | |
Initial symptom (rest tremor/gait) | – | 48%/15% | |
Freezing of gait reported at visit | – | 37% | |
Age at onset (years) | – | 60.1 ± 10.3 | |
Disease duration (years) | – | 9.2 ± 5.7 | |
Hoehn & Yahr score | – | 2.1 ± 0.8 | |
Daily levodopa dose (mg/day) | – | 667 ± 368 (n = 23) | |
levodopa per dose (mg/dose) | – | 194 ± 84 (n = 23) | |
Duration on levodopa (years) | – | 5.3 ± 3.2 (n = 23) | |
On dopamine agonist at visit | – | 7% | |
On MAO-I at visit | – | 33% | |
LEDD (l-dopa + agonist + MAO-I) | – | 695 ± 393 (n = 24) |
